Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients

被引:55
作者
Chen, Qingyong [1 ]
Fei, Jun [1 ]
Wu, Lijun [1 ]
Jiang, Zhongyong [1 ]
Wu, Yuquan [1 ]
Zheng, Yun [1 ]
Lu, Guohua [2 ]
机构
[1] 117th Hosp PLA, Dept Resp Dis, Hangzhou 310013, Zhejiang, Peoples R China
[2] Zhejiang Univ, Dept Resp Dis, Affiliated Hosp 1, Coll Med, Hangzhou 310004, Zhejiang, Peoples R China
关键词
cathepsin B; cathepsin L; cysteine C; urokinase plasminogen activator; urokinase plasminogen activator receptor; lung cancer; progonosis; sera; INHIBITORS STEFIN-A; PROGNOSTIC-SIGNIFICANCE; PULMONARY ADENOCARCINOMAS; CLINICAL-SIGNIFICANCE; CYSTEINE PROTEINASES; COLORECTAL-CANCER; EXPRESSION; METASTASIS; PROTEASES; PROGRESSION;
D O I
10.3892/ol.2011.302
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study aimed to determine the levels of cathepsin B (cath B), cathepsin L (cath L), cystatin C, urokinase plasminogen activator (u-PA) and urokinase plasminogen activator receptor (u-PAR) in the sera of patients with lung cancer compared to healthy controls using ELISA. Concomitantly, the relationship between the components and clinicopathological prognosis was analyzed. The study included 30 healthy volunteers and 105 lung cancer patients. Blood samples were collected and cath B, cath L, cystatin C, u-PA and u-PAR measurements were made using ELISA. Results showed that the levels of cath B, cath L, cystatin C, u-PA and u-PAR were significantly higher in the patient group compared to the healthy controls. The significance was marked for cath B and mild for u-PAR in correlation with lymph node metastasis. There was no significance for other parameters. Notably, patients with a combination of high cystatin C and high cath B levels had significantly lower survival probability as compared to those with cystatin C(+)/cath B(-) or with cystatin C(-)/cath B(-), Similarly, patients with a combination of high u-PA and u-PAR experienced significantly shorter survival., Furthermore, the univariate analysis revealed that cath B, u-PAR, lymph node metastases, stage and grade were related to survival. However, findings of the multivariate Cox analysis indicated that the sera levels of cath B, u-PAR and lymph node metastases may serve as independent prognostic variables in patients with lung cancer.
引用
收藏
页码:693 / 699
页数:7
相关论文
共 50 条
[31]   EFFECTIVE ACTIVATION OF THE PROENZYME FORM OF THE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (PRO-UPA) BY THE CYSTEINE PROTEASE CATHEPSIN-L [J].
GORETZKI, L ;
SCHMITT, M ;
MANN, K ;
CALVETE, J ;
CHUCHOLOWSKI, N ;
KRAMER, M ;
GUNZLER, WA ;
JANICKE, F ;
GRAEFF, H .
FEBS LETTERS, 1992, 297 (1-2) :112-118
[32]   Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: Relation to prognosis and angiogenesis [J].
Offersen, Birgitte Vrou ;
Pfeiffer, Per ;
Andreasen, Peter ;
Overgaard, Jens .
LUNG CANCER, 2007, 56 (01) :43-50
[33]   Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist [J].
Ignar, DM ;
Andrews, JL ;
Witherspoon, SM ;
Leray, JD ;
Clay, WC ;
Kilpatrick, K ;
Onori, J ;
Kost, T ;
Emerson, DL .
CLINICAL & EXPERIMENTAL METASTASIS, 1998, 16 (01) :9-20
[34]   Gene expression changes of urokinase plasminogen activator and urokinase receptor in rat testes at postnatal stages [J].
Huang, Dong-Hui ;
Zhao, Hu ;
Tian, Yong-Hong ;
Li, Hong-Gang ;
Ding, Xiao-Fang ;
Xiong, Cheng-Liang .
ASIAN JOURNAL OF ANDROLOGY, 2007, 9 (05) :679-683
[35]   Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist [J].
Ignar D.M. ;
Andrews J.L. ;
Witherspoon S.M. ;
Leray J.D. ;
Clay W.C. ;
Kilpatrick K. ;
Onori J. ;
Kost T. ;
Emerson D.L. .
Clinical & Experimental Metastasis, 1998, 16 (1) :9-20
[36]   The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia [J].
Erkut, Nergiz ;
Mentese, Ahmet ;
Ozbas, Hasan Mucahit ;
Ermantas, Nilay ;
Sumer, Aysegul ;
Orem, Asim ;
Sonmez, Mehmet .
TURKISH JOURNAL OF HEMATOLOGY, 2016, 33 (02) :135-140
[37]   Novel protein interactors of urokinase-type plasminogen activator receptor [J].
Mekkawy, Ahmed H. ;
De Bock, Charles E. ;
Lin, Zhen ;
Morris, David L. ;
Wang, Yao ;
Pourgholami, Mohammad H. .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 399 (04) :738-743
[38]   The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma [J].
Zhu Chengjun ;
Jiang Lu ;
Xu Jun ;
Ren Anjing ;
Ju Feng ;
Shu Yongqian .
PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (04)
[39]   The soluble urokinase plasminogen activator receptor and its fragments in venous ulcers [J].
Ahmad, Anwar ;
Saha, Prakash ;
Evans, Colin ;
Thurison, Tine ;
Hoyer-Hansen, Gunilla ;
Patel, Ashish ;
Modarai, Bijan ;
Smith, Alberto .
JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS, 2015, 3 (02) :190-197
[40]   The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility [J].
Kjoller, L .
BIOLOGICAL CHEMISTRY, 2002, 383 (01) :5-19